Introduction and hypothesis We describe the rationale and methodology for a study comparing mind-body treatment and pharmacotherapy in women with urgency urinary incontinence (UUI). To explore brain associations in UUI, a subset of patients will also undergo functional magnetic resonance imaging (fMRI). We hypothesize that hypnotherapy, a mindbody intervention, will be at least as effective as pharmacotherapy in treating UUI. We also hypothesize that fMRI findings will change following treatment, with changes potentially differing between groups. Methods We describe the development and design challenges of a study comparing the efficacy of hypnotherapy and conventional pharmacotherapy in the treatment of UUI. The study randomizes women to either of these treatments, and outcome measures include bladder diaries and validated questionnaires. Sample size estimates, based on a noninferiority test (alpha = 0.025, beta = 0.20), after considering dropout subjects and subjects lost to follow-up, indicated that approximately 150 woman would be required to test the hypothesis that hypnotherapy is not inferior to pharmacotherapy within a 5 % noninferiority margin. The study will also evaluate fMRI changes in a subset of participants before and after therapy. Challenges included designing a study with a mind-body therapy and a comparison treatment equally acceptable to participants, standardizing the interventions, and confronting the reality that trials are time-consuming for participants who have to make appropriate accommodations in their schedule. Results Study enrollment began in March 2013 and is ongoing. Conclusions We describe the design of a randomized controlled trial comparing mind-body therapy and pharmacotherapy in the treatment of UUI and the challenges encountered in its implementation.
Introduction
Urgency urinary incontinence (UUI) is common, economically burdensome and life-altering [1, 2] . Standard pharmacologic treatments for UUI are limited by their side effects relative to their efficacy [3] . UUI focus groups have highlighted patients' Bdesperate quest for (its) cause…and cure^ [4] . Inadequate understanding of UUI pathophysiology has critically hampered clinicians' ability to meet patient needs. Increased awareness that UUI is a functional disorder may enhance its understanding. Patients with functional disorders, including irritable bowel syndrome (IBS) and UUI, exhibit increased visceral sensitivity to physiologic stimulation (e.g. bowel or bladder distension). This increased visceral sensitivity is of uncertain etiology, confounding the ability to treat these disorders.
Recently, brain imaging studies have shown differences in brain activity in patients with functional disorders,including those with IBS [5, 6] and UUI [7] [8] [9] , indicating the existence of a brainbody connection. These findings raise the possibility that brainbody interventions may play a role in the treatment of these disorders. Mind-body therapies have been reported to improve IBS symptoms [10, 11] , and results from our group's hypnotherapy pilot study and reports by others also suggest that mind-body treatments improve UUI [12, 13] . Based on these findings, we designed a randomized controlled trial (RCT) to compare the efficacy of hypnotherapy and pharmacotherapy in the treatment of women with UUI. Using functional magnetic resonance imaging (fMRI), this same study was also designed to assess potential brain changes following UUI treatment. We describe here the design of this study and the challenges encountered in its implementation.
Materials and methods

Study aims and hypotheses
The study has two components. The clinical component is an RCT comparing the efficacy of hypnotherapy and pharmacotherapy in the treatment of UUI. We hypothesized that among patients with UUI, hypnotherapy is at least as effective as pharmacotherapy in diminishing the severity of UUI symptoms. The study's translational component uses fMRI to investigate a subgroup of women enrolled in the RCT, with fMRI performed before and after treatment. We hypothesized that hypnotherapy will decrease abnormal brain activation in patients with UUI and will modulate brain functional connectivity, and we will investigate whether this normalization is greater in women undergoing hypnotherapy than in those receiving pharmacotherapy. The fMRI methods and baseline findings have been previously published [14] .
The primary aim of this study's clinical component is to compare the effectiveness of hypnotherapy and pharmacotherapy based on 3-day voiding diaries following 8 weeks of treatment. Secondary clinical aims included evaluation of changes in UUI symptoms and sexual function and potential changes in other functional abnormalities (including IBS and interstitial cystitis) based on validated questionnaires at 8 weeks. All parameters will also be evaluated during follow-up at 6 and 12 months.
The fMRI portion of this study is based on prior work which found that women with UUI differ in brain activation on fMRI compared to controls [7] [8] [9] . fMRI uses the brain oxygen level dependent (BOLD) signal on brain imaging as an indicator of neuronal activity. fMRI researchers commonly administer stimuli, or Btasks^, to elicit changes in the BOLD signal to evaluate the differences between patients and controls [14] . UUI researchers have commonly used bladder filling as that task [7, 8, 14] . In addition to task-oriented brain activation, specific brain regions also demonstrate similar fluctuations in BOLD signal over time that are intrinsic in nature [15] . Areas of the brain that show coherent neural activation and deactivation are described as demonstrating Bfunctional connectivity^, and together constitute Bfunctional networks^. One method of assessing these functional networks is to use brain sites that activate during a task as seed points and then determine if these seed points coactivate with other sites when the brain is at rest. This is called Bseed-based resting state connectivity analysis [ 15] . Seed-based resting state connectivity analysis will be used in this study to compare network differences between patients and controls before and after treatment. One benefit of this resting state analysis is that it minimizes confounding effects of subject adaptation to a repeated task.
The translational aims of the fMRI portion of this study are to determine whether brain activation and connectivity change following treatment, to determine whether hypnotherapy is associated with greater modification of brain activation and connectivity than pharmacotherapy, and to determine whether fMRI changes are associated with treatment efficacy. We have reported the fMRI methodology and baseline differences in patients and controls [14] , and will evaluate fMRI changes in patients following RCT interventions at 8 weeks.
Overall study design and flow of participants Figure 1 illustrates the progression of the UUI participants through the study. The pharmacotherapy group receives anticholinergic medication with weekly interaction with a pharmacotherapy counselor for 8 weeks. The hypnotherapy group receives weekly hypnotherapy sessions with a licensed clinical hypnotherapist for 8 weeks. Participants complete initial follow-up after 8 weeks of treatment. The pharmacotherapy group continues anticholinergics and the hypnotherapy group is encouraged to practice self-hypnosis with follow-up at 6 and 12 months. The study received IRB approval (09-314) and all participants give written, informed consent.
Inclusion and exclusion criteria
The study targets women with idiopathic UUI who are naive to therapy or with minimal exposure to pharmacotherapy. The inclusion and exclusion criteria for the RCT and fMRI components of the study are listed below. 
RCT
Participant screening, recruitment and enrollment
Potential study candidates are recruited from the University of New Mexico Health Sciences Center Clinics and the community. Recruitment tools include study flyers, radio advertisements, community outreach seminars and informational sessions for primary care providers. Potential candidates are identified by clinicians and study coordinators and are administered the OAB-q SF, a validated tool which clinically screens for OAB symptoms; participants are required to have a score <8 [16] . Coordinators fully discuss the study with candidates, provide them with a copy of the consent and allow appropriate time to consider study participation. Women who had previously taken oxybutynin and tolterodine without improvement are informed that they will not benefit from study participation and they are, therefore, not enrolled in the study. After providing consent, women are enrolled and baseline evaluations are performed.
Randomization and masking
Approximately 150 -160 women will be randomized to either hypnotherapy or pharmacotherapy after baseline assessments are completed. The randomization scheme is computer generated with varying permuted block sizes of four to eight, stratified for fMRI performance and baseline UUI severity (up to three UUI episodes versus four or more episodes in 3-day voiding diary). Group assignments are placed in opaque, sealed envelopes at study initiation by individuals otherwise unassociated with the study. These are opened at randomization. The interventions do not allow participant masking (i.e. participants know if they are receiving pharmacotherapy or hypnotherapy). The study personnel coordinating study visits, hypnotherapists and medication counselors are not masked. The investigators, personnel responsible for primary data entry, and the statistician are masked to participant treatment. Data collected include only the participants' research numbers to maintain masking. Double data entry is performed and data are reviewed for discrepancies which are reconciled quarterly.
RCT interventions
During the baseline study visit all participants receive written information regarding standard behavioral therapy, including life-style modification and pelvic floor exercise.
Hypnosis and hypnotherapist requirements
Hypnotherapy is: BThe induction of a trance-like state to facilitate relaxation and…use of enhanced suggestibility to treat psychologic and medical conditions and effect behavioral changes^ [17] . Hypnosis is often induced by asking subjects to close their eyes, and then to progressively relax their muscles. This is followed by the use of deepening techniques. Suggestions for normalization of function and sensitivity are made using both imagery and conditioning techniques [18] . According to the American Psychological Association, 'introduction' and 'suggestion' are necessary components, stating BHypnosis typically involves an introduction…during which the patient is told that suggestions for imaginative experiences will be presented. The hypnotic induction is an extended initial suggestion for using one's imagination, and may contain further elaborations of the introduction. The hypnotic procedure is used to encourage and evaluate responses to suggestions. When using hypnosis, one person (the subject) is guided by another (the hypnotist) to respond to suggestions for changes in subjective experience, alterations in perception, sensation, emotion, thought or behavior^ [19, 20] . Investigators have suggested that hypnosis alters sensory awareness and cognitive processing in response to external stimuli and, as shown on fMRI, modulates activation of the limbic cortex in response to those stimuli [21, 22] . All study hypnotherapists are members of the International Board of Hypnotherapy, are board-certified, have completed >400 hours of hypnotherapy training from a state licensed school and passed a written examination. The board requires members to adhere to their scope of practice and code of ethics, maintain independent liability coverage and complete annual continuing education requirements.
Hypnotherapists and hypnotherapy sessions
Participants are assigned to one of four clinical hypnotherapists affiliated with the study who administer the sessions in a standardized fashion (Table 1 ). The study's coinvestigator (R.E.S.), a physician, certified hypnotherapist and hypnotherapy instructor, coauthored the study's hypnotherapy manual. Study hypnotherapists received 4 hours of additional training from R.E.S. and are clinically overseen by him. Study sessions are administered as eight 1-hour sessions over 8 weeks in outpatient offices. Hypnotherapists provide their patients with individually designed hypnotherapy recordings after session 2 or 3 to assist the patients with the performance of selfhypnosis.
Medication
Long-acting oxybutynin 10 mg/day is initially dispensed to women randomized to pharmacotherapy. If there is marginal success with oxybutynin, long-acting tolterodine 4 mg/day is given as an alternative (or vice versa). Participants may switch between these drugs if they find the side effects/efficacy of either unacceptable.
Medication counselor and counseling sessions
Eight sessions are administered over 8 weeks with the medication counselor in the outpatient setting ( Table 1 ). The counselor, a research coordinator with a medical background whose only responsibility to the study is to provide medication counseling, received 4 h of counseling instruction from a study investigator (Y.
fMRI procedures
Approximately 60 -70 UUI patients will participate in the baseline study and 8-week follow-up fMRI study (Fig. 1) . Participation in the fMRI study is offered to women according to the inclusion/exclusion criteria upon enrollment into the RCT. Patients are enrolled in a sequential fashion throughout the study until the fMRI enrollment target is met. Details of the procedures, including the fMRI task, data acquisition and processing, and analytic methods have been previously reported [14] . In brief, before fMRI, bedside cystometry is [14] .
Outcome measures and other measured variables
RCT
The RCT study outcomes are measured before randomization, after 2 months of treatment and during follow-up at 6 and 12 months. The primary outcome measure is the difference in the change in the number of UUI episodes between the pharmacotherapy and the hypnotherapy group at 2 months based on the 3-day voiding diary. Diaries are evaluated, as outlined in the study manual by at least two research coordinators. Disagreements in diary interpretation are adjudicated at a meeting attended by at least three research personnel. Secondary outcomes include between-group differences in UUI episodes in the voiding diary at 6 and 12 months, between-group differences in UUI symptoms and sexual function at 2, 6 and 12 months based on the following validated questionnaires: the OAB-q SF [23] , the Incontinence Severity Index [24] , the Patient Perception of Bladder Condition [25] , and the Prolapse and Incontinence Sexual Questionnaire-12 [26] . Other functional abnormalities which may co-occur with UUI will be measured,including interstitial cystitis/bladder pain syndrome and IBS based on validated questionnaires (the Bladder Pain Interstitial Cystitis Symptom Scale [27] including an additional visual analogue scale which documents the duration of symptoms, the Colo-Rectal Anal Distress Inventory-8 [28] , and the IBS Diagnostic Module [29] ) administered at baseline and at 2, 6 and 12 months. The questionnaires are presented in more detail in Table 2 .
Other variables
Patient characteristics are obtained at enrollment, including age, parity, surgical and medical history. Body mass index and vital signs are recorded. The pelvic organ prolapse quantitation (POP-Q) examination is performed if POP-Q results are unavailable within the last year. A clinical hypnotherapist administers the Stanford Hypnotic Susceptibility Scale [30] to all participants, the results of which will be analyzed at study completion to evaluate whether hypnotic susceptibility affects treatment efficacy. A trained research nurse performs bedside cystometric testing prior to randomization. The participants enrolled in the fMRI portion of the study undergo fMRI at a separate visit before randomization.
Immediately following randomization and before treatment, all participants respond to the statement, BI expect that my treatment will improve my urgency urinary incontinence problems^with five possible answers ranging from 'strongly disagree' to 'strongly agree' to measure the association between participant expectations and treatment efficacy. At treatment follow-up, participants respond to the statement, BMy treatment met my expectations for treating my urgency urinary incontinence problems^with possible answers ranging from 'strongly disagree' to 'strongly agree'. Treatment compliance is also tracked during follow-up at 2, 6 and 12 months. The pharmacotherapy group is asked whether they are still taking their medications and the hypnotherapy group is asked whether they are still performing self-hypnosis and/or listening to their hypnotherapy recordings. This information will be used to help ascertain the effect that self-hypnosis practice and medication compliance has on the study outcomes.
Analytic strategies
RCT sample size calculation
Investigators performed sample size calculations for change in UUI episodes and change inOAB-q SF scores based on pilot data and the literature [3, 12] , utilizing a noninferiority design for the primary outcome (difference in the change in the number of UUI episode between the hypnotherapy group and the pharmacotherapy group). A one-sided noninferiority test with alpha = 0.025 and a noninferiority margin of 5 % was used. If μ_h is the population mean percent reduction in the number of UUI episodes in the hypnotherapy group, and μ_m is the population mean percent reduction in the number of UUI episodes in the pharmacotherapy group, investigators will test the hypothesis (H_0: μ_h − μ_m ≤ −5) against the one-sided alternative (H_0: μ_h − μ_m > −5) using a significance level of 0.025. If the null hypothesis is rejected, investigators may conclude that hypnotherapy is not inferior to pharmacotherapy, on average, by more than 5 %, and in fact may be superior to pharmacotherapy, in percent reduction in UUI episodes. The test may be performed by computing the lower 97.5 % one-sided confidence bound for μ_h − μ_m. If the lower confidence bound exceeds −5 %, noninferiority of hypnotherapy will be concluded,, and if it exceeds zero, superiority will be concluded. Assuming drop-out, withdrawal and missing data rates as high as 33 %, approximately 52 subjects will be available for analysis in both groups. If μ_h − μ_m ≥ 9 %, the sample size would provide a power of ≥80 % for noninferiority testing. Improvement will be compared between groups at baseline and during follow-up at 2, 6 and 12 months.
RCT analysis
Parameters will be compared using a generalized linear mixed model analysis. If baseline differences between groups are found, appropriate variables will be added to the analysis as covariates. Primary analyses will be performed using intention to treat. Per protocol analysis will additionally be performed. Similar analyses will be performed comparing group differences in change in questionnaire scores.
Analysis for fMRI
Whole-brain voxel-wise analysis will be performed evaluating the BOLD signal during bladder filling in UUI subjects before treatment and controls as described previously [14] . Taskrelated differences in brain activation between UUI subjects and controls were observed in multiple sites including the cingulate cortex and insula. For fMRI evaluation during follow-up at 2 months compared to baseline, investigators will measure between-group and within-group change in activation and connectivity. A linear mixed effects model will be used.
Results
Study enrollment began in March 2013 and is ongoing. Analysis awaits initial 2-month study completion, projected to occur at the end of 2016 with 1 year follow-up in 2017. The control versus UUI patient baseline fMRI findings have been reported [14] .
Discussion
We describe here the study's methodology, the difficulties encountered and approaches to overcoming these difficulties.
Study challenges
Feasibility and recruitment
A major challenge was to design a study with differing interventions (behavioral versus pharmacologic) but acceptable to potential participants. Hypnotherapy involves significant personal contact with the hypnotherapist. We strengthened the interpersonal contact associated with the pharmacotherapy treatment arm with the addition of a medication counselor. The delivery of routine/standard-of-care behavioral therapy for both treatment arms was made more comparable by providing all participants with a life-style handout at study entry (reviewing fluid intake, timed voiding, urge suppression strategies), and discussing life-style modifications weekly with hypnotherapy and medication counselors. Another challenge for this and any behavioral study is the time-consuming nature of the interventions. It is difficult for women to commit to eight weekly treatment sessions. Time demands could deter enrollment. We address this problem first by having hypnotherapists available for sessions during evenings and weekends, and second by having the medication counselor contact patients at times patients deem convenient, offering phone calls if the patient prefers. Due to these efforts, enrollment continues within its projected time-frame. Unlike many studies which evaluate behavioral or pharmacotherapy interventions, this study will follow participants for 1 year. The aim is to evaluate whether the interventions have longer term acceptability and durability.
Group assignment
As with any RCT, participants cannot choose their intervention. Studies cannot rid participants of their pretreatment biases or preconceptions regarding differences in treatment efficacy. Participants respond to an expectation of treatment success statement following randomization and before treatment to ascertain if pretreatment expectations are associated with treatment success.
Standardization of treatments
To address this issue, both treatment interventions are clearly outlined in treatment manuals which were reviewed with the interventionists (hypnotherapists, medication counselors) at study initiation. Interventionists received equal amounts of educational time and instruction. Pharmacotherapy and hypnotherapy sessions are recorded and audited by study personnel who are not involved with study design and analysis. The auditors evaluate the sessions using fidelity checklists to ensure the interventionists include the important elements of treatment.
fMRI Design and implementation of the fMRI task presented a unique set of challenges, as discussed more fully previously [14] . To allay unnecessary participant anxiety and decrease the likelihood that fluid infusions would result in incontinence, participants undergo simulation of the task following cystometric testing. In the occasional patient who is observed by the research nurse to have undue anxiety during the simulation, the fluid volumes are adjusted to predetermined lower volumes outlined in the manual of operations. Participants also undergo repeated education regarding what to expect in the scanner on the day of the fMRI scan. fMRI personnel use a script to inform the patients what to expect just before performance of the scan. The study coordinator accompanies the patient to the fMRI scanner, remaining in the scan room to decrease patient anxiety.
Potential study benefits
This study has a number of potential benefits. Women in this study, similar to subjects enrolled in other trials, benefit from the individualized attention and education they receive as study participants. Study coordinators and counselors have repeated contact with all study participants. Whether these benefits are durable over the longer term will be evaluated during follow-up at 6 and 12 months. This study is, to our knowledge, the only trial comparing this novel treatment, hypnosis, with a standard treatment, anticholinergic medication. In a 1982 case series of 50 women with UUI, 29 (58 %) were symptom-free following 12 hypnotherapy sessions, an additional 14 (28 %) were improved, and 7 (14 %) remained unchanged [13] . Despite these reported improvements, an appropriately powered RCT utilizing hypnotherapy in UUI is lacking. Should this endeavor shows that hypnotherapy treats UUI as effectively as standard therapy, it could expand therapeutic options for women with this chronic condition. Furthermore, it could lead the way in efforts to treat UUI with other mind-body therapies.
The fMRI portion of the study could also help both UUI clinicians and patients understand how the mind is affected by UUI and understand the role neuroplasticity plays in this condition. The study may highlight similarities or differences on fMRI associated with a mind-body therapy compared with pharmacotherapy.
This study does have several limitations which include the time required by the participants for the RCT, potential lack of availability of board-certified hypnotherapists, and the possibility that changes on fMRI will not be found in patients following treatment. The strengths of the study, as noted above, include the standardization of the two interventions, the plan to follow participants for 1 year and the design of the RCT comparing hypnotherapy and pharmacotherapy in UUI.
In summary, this article explains the problems encountered in the design and implementation of the study comparing a complementary alternative/integrative health therapy with traditional therapy. Its lessons may assist in the design of future mind-body research.
